Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Familial Dysautonomia Follow-up

  • Author: Robert A D'Amico, MD, FACS; Chief Editor: Hampton Roy, Sr, MD  more...
 
Updated: Jan 05, 2016
 

Further Outpatient Care

At New York University Medical Center, a Dysautonomia Treatment and Evaluation Center examines patients with familial dysautonomia (FD) on a regular schedule to provide comprehensive care plans. It serves as a resource for patients, families, and health providers.

Next

Deterrence/Prevention

No means of preventing the disorder exists at this time, but with symptomatic and supportive treatments, morbidity and mortality have been reduced and quality of life enhanced.

Previous
Next

Prognosis

Educate parents and patients regarding daily eye care and early warning signs of corneal problems, as well as use of punctal cautery. This education has resulted in decreased corneal scarring and decreased the need for more aggressive surgical measures, such as tarsorrhaphy, conjunctival flaps, and corneal transplants.

Previous
Next

Patient Education

Teach patients and parents to instill topical lubricants frequently and to be alert for early warning signs of corneal erosion and infection.

Use eye protective devices (eg, goggles, moisture chambers, scleral lenses) when topical medications are not sufficient.

Previous
 
Contributor Information and Disclosures
Author

Robert A D'Amico, MD, FACS Chairman, Department of Ophthalmology, Richmond University Medical Center; Clinical Professor, Department of Ophthalmology, New York University School of Medicine

Robert A D'Amico, MD, FACS is a member of the following medical societies: Association for Research in Vision and Ophthalmology, Medical Society of the State of New York, New York Academy of Medicine, International Society for Genetic Eye Diseases and Retinoblastoma, Transplantation Society, Cornea Society, Association of University Professors of Ophthalmology, Xenotransplantation Society, American Academy of Ophthalmology, American College of Surgeons, American Medical Association

Disclosure: Nothing to disclose.

Coauthor(s)

Felicia B Axelrod, MD Director of Dysautonomia Treatment and Evaluation Center, Carl Seaman Family Professor for Dysautonomia Treatment and Research, Professor, Departments of Pediatrics and Neurology, New York University School of Medicine

Felicia B Axelrod, MD is a member of the following medical societies: American Academy of Pediatrics, American Autonomic Society, American Medical Association, American Pediatric Society, Society for Pediatric Research

Disclosure: Nothing to disclose.

Specialty Editor Board

Simon K Law, MD, PharmD Clinical Professor of Health Sciences, Department of Ophthalmology, Jules Stein Eye Institute, University of California, Los Angeles, David Geffen School of Medicine

Simon K Law, MD, PharmD is a member of the following medical societies: American Academy of Ophthalmology, Association for Research in Vision and Ophthalmology, American Glaucoma Society

Disclosure: Nothing to disclose.

Chief Editor

Hampton Roy, Sr, MD Associate Clinical Professor, Department of Ophthalmology, University of Arkansas for Medical Sciences

Hampton Roy, Sr, MD is a member of the following medical societies: American Academy of Ophthalmology, American College of Surgeons, Pan-American Association of Ophthalmology

Disclosure: Nothing to disclose.

Additional Contributors

Andrew W Lawton, MD Neuro-Ophthalmology, Ochsner Health Services

Andrew W Lawton, MD is a member of the following medical societies: American Academy of Ophthalmology, Arkansas Medical Society, Southern Medical Association

Disclosure: Nothing to disclose.

References
  1. Axelrod FB. Familial dysautonomia. Muscle Nerve. 2004 Mar. 29(3):352-63. [Medline].

  2. Axelrod FB. A world without pain or tears. Clin Auton Res. 2006 Apr. 16(2):90-7. [Medline].

  3. Riley CM, Day RL, Greeley DM. Central autonomic dysfunction with defective lacrimation: report of five cases. Pediatrics. 1949. Vol. 3: 468-77.

  4. Anderson SL, Coli R, Daly IW, et al. Familial dysautonomia is caused by mutations of the IKAP gene. Am J Hum Genet. 2001 Mar. 68(3):753-8. [Medline].

  5. Leyne M, Mull J, Gill SP, et al. Identification of the first non-Jewish mutation in familial Dysautonomia. Am J Med Genet A. 2003 May 1. 118A(4):305-8. [Medline].

  6. Slaugenhaupt SA, Blumenfeld A, Gill SP, et al. Tissue-specific expression of a splicing mutation in the IKBKAP gene causes familial dysautonomia. Am J Hum Genet. 2001 Mar. 68(3):598-605. [Medline].

  7. Pearson J, Pytel BA, Grover-Johnson N, et al. Quantitative studies of dorsal root ganglia and neuropathologic observations on spinal cords in familial dysautonomia. J Neurol Sci. 1978 Jan. 35(1):77-92. [Medline].

  8. Axelrod FB, Goldberg JD, Ye XY, et al. Survival in familial dysautonomia: Impact of early intervention. J Pediatr. 2002 Oct. 141(4):518-23. [Medline].

  9. Brunt PW, McKusick VA. Familial dysautonomia. A report of genetic and clinical studies, with a review of the literature. Medicine (Baltimore). 1970 Sep. 49(5):343-74. [Medline].

  10. Porges RF, Axelrod FB, Richards M. Pregnancy in familial dysautonomia. Am J Obstet Gynecol. 1978 Nov 1. 132(5):485-8. [Medline].

  11. Elkayam L, Matalon A, Tseng CH, et al. Prevalence and severity of renal disease in familial dysautonomia. Am J Kidney Dis. 2006 Nov. 48(5):780-6. [Medline].

  12. Clayson D, Welton W, Axelrod FB. Personality development and familial dysautonomia. Pediatrics. 1980 Feb. 65(2):269-74. [Medline].

  13. Sands SA, Giarraffa P, Jacobson CM, et al. Familial dysautonomia's impact on quality of life in childhood, adolescence, and adulthood. Acta Paediatr. 2006 Apr. 95(4):457-62. [Medline].

  14. Welton W, Clayson D, Axelrod FB, et al. Intellectual development and familial dysautonomia. Pediatrics. 1979 May. 63(5):708-12. [Medline].

  15. Axelrod FB, Iyer K, Fish I, et al. Progressive sensory loss in familial dysautonomia. Pediatrics. 1981 Apr. 67(4):517-22. [Medline].

  16. Blumenfeld A, Slaugenhaupt SA, Axelrod FB, et al. Localization of the gene for familial dysautonomia on chromosome 9 and definition of DNA markers for genetic diagnosis. Nat Genet. 1993 Jun. 4(2):160-4. [Medline].

  17. Axelrod FB, Liebes L, Gold-Von Simson G, Mendoza S, Mull J, Leyne M, et al. Kinetin improves IKBKAP mRNA splicing in patients with familial dysautonomia. Pediatr Res. 2011 Nov. 70(5):480-3. [Medline]. [Full Text].

  18. Cohen-Kupiec R, Pasmanik-Chor M, Oron-Karni V, Weil M. Effects of IKAP/hELP1 deficiency on gene expression in differentiating neuroblastoma cells: implications for familial dysautonomia. PLoS One. 2011 Apr 29. 6(4):e19147. [Medline]. [Full Text].

  19. Axelrod FB, Goldstein DS, Holmes C, et al. Pattern of plasma levels of catecholamines in familial dysautonomia. Clin Auton Res. 1996 Aug. 6(4):205-9. [Medline].

  20. Axelrod FB, Goldberg JD, Rolnitzky L, et al. Fludrocortisone in patients with familial dysautonomia--assessing effect on clinical parameters and gene expression. Clin Auton Res. 2005 Aug. 15(4):284-91. [Medline].

  21. Axelrod,FB, D’Amico,RA. Familial Dysautonomia. Fraunfelder FT, Roy H, Eds. Ocular Therapy 2. Philadelphia, PA: WB Saunders; 1985. 200-1.

  22. Diamond GA, D'Amico RA, Axelrod FB. Optic nerve dysfunction in familial dysautonomia. Am J Ophthalmol. 1987 Dec 15. 104(6):645-8. [Medline].

  23. Mendoza-Santiesteban CE, Hedges TR 3rd, Norcliffe-Kaufmann L, Warren F, Reddy S, Axelrod FB, et al. Clinical Neuro-ophthalmic Findings in Familial Dysautonomia. J Neuroophthalmol. 2011 Sep 13. [Medline].

  24. Bernardi L, Hilz M, Stemper B, et al. Respiratory and cerebrovascular responses to hypoxia and hypercapnia in familial dysautonomia. Am J Respir Crit Care Med. 2003 Jan 15. 167(2):141-9. [Medline].

  25. Maayan C, Carley DW, Axelrod FB, et al. Respiratory system stability and abnormal carbon dioxide homeostasis. J Appl Physiol. 1992 Mar. 72(3):1186-93. [Medline].

  26. Roach ES, Miller VS, eds. Neurocutaneous Disorders. Cambridge University Press; 2004.

  27. Aragona P, Papa V, Micali A, et al. Long term treatment with sodium hyaluronate-containing artificial tears reduces ocular surface damage in patients with dry eye. Br J Ophthalmol. 2002 Feb. 86(2):181-4. [Medline].

  28. Pflugfelder SC. Antiinflammatory therapy for dry eye. Am J Ophthalmol. 2004 Feb. 137(2):337-42. [Medline].

  29. Anderson SL, Qiu J, Rubin BY. Tocotrienols induce IKBKAP expression: a possible therapy for familial dysautonomia. Biochem Biophys Res Commun. 2003 Jun 20. 306(1):303-9. [Medline].

  30. Ilsar M, Hartstein ME, Maayan C. Punctal occlusion in patients with familial dysautonomia. Ann Ophthalmology. 1998. 30(6):375-378.

  31. Rosenthal P, Cotter JM, Baum J. Treatment of persistent corneal epithelial defect with extended wear of a fluid-ventilated gas-permeable scleral contact lens. Am J Ophthalmol. 2000 Jul. 130(1):33-41. [Medline].

  32. Le HG, Tang M, Ridges R, Huang D, Jacobs DS. Pilot Study for OCT Guided Design and Fit of a Prosthetic Device for Treatment of Corneal Disease. J Ophthalmol. 2012. 2012:812034. [Medline]. [Full Text].

  33. Bonini S, Lambiase A, Rama P, et al. Topical treatment with nerve growth factor for neurotrophic keratitis. Ophthalmology. 2000 Jul. 107(7):1347-51; discussion 1351-2. [Medline].

  34. Matsumoto Y, Dogru M, Goto E, et al. Autologous serum application in the treatment of neurotrophic keratopathy. Ophthalmology. 2004 Jun. 111(6):1115-20. [Medline].

  35. Kojima T, Ishida R, Dogru M, et al. The effect of autologous serum eyedrops in the treatment of severe dry eye disease: a prospective randomized case-control study. Am J Ophthalmol. 2005 Feb. 139(2):242-6. [Medline].

  36. Chen HJ, Pires RT, Tseng SC. Amniotic membrane transplantation for severe neurotrophic corneal ulcers. Br J Ophthalmol. 2000 Aug. 84(8):826-33. [Medline]. [Full Text].

  37. Tseng SC, Espana EM, Kawakita T, et al. How does amniotic membrane work?. Ocul Surf. 2004 Jul. 2(3):177-87. [Medline].

  38. Dohlman C, Waller S, Netland P. Keratoprosthesis Surgery. Lindquist T, Lindstrom R, eds. Ophthalmic Surgery. 1996. Vol L: 1-32.

  39. Ngai J, Kreynin I, Kim JT, et al. Anesthesia management of familial dysautonomia. Paediatr Anaesth. 2006 Jun. 16(6):611-20. [Medline].

  40. Axelrod FB. Familial dysautonomia. Burg FD, Ingelfinger JR, Polin RA, eds. Current Pediatric Therapy. 15th ed. Philadelphia, Pa: WB Saunders Co; 1996. 91-94.

  41. Axelrod FB. Familial dysautonomia: a review of the current pharmacological treatments. Expert Opin Pharmacother. 2005 Apr. 6(4):561-7. [Medline].

Previous
Next
 
Absence of fungiform papillae on the tongue. The highly vascularized fungiform papillae on the anterior third of the tongue are absent resulting in a smooth and glistening tongue tip.
Lack of axon flare following intradermal histamine. Histamine phosphate in a 1:10,000 dilution injected intradermally does not produce pain or an axon flare.
Erosion and scarring of the inferior cornea due to incomplete lid closure during sleep.
Neurotrophic corneal ulcer.
Corneal stromal opacification.
Bipedicle tarsorrhaphy.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.